Skip to content

A prospective split-face control study of fractional 1064nm picosecond laser and non-ablative fractional 1565nm laser in the treatment of enlarged pores

A prospective split-face control study of fractional 1064nm picosecond laser and non-ablative fractional 1565nm laser in the treatment of enlarged pores

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051254
Enrollment
Unknown
Registered
2021-09-17
Start date
2020-10-01
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Enlarged Pores

Interventions

1:1064nm laser
2:1565nm laser

Sponsors

Huashan Hospital affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
24 Years to 32 Years

Inclusion criteria

Inclusion criteria: 1. Adults aged 18-60 years with enlarged facial pores; 2. The area and severity of enlarged pores should be in similar severity on both sides of face; 3. Subjects should sign the informed consent, and be willing to comply with the trial treatment, follow-up and evaluation requirements.

Exclusion criteria

Exclusion criteria: 1. Those who have received treatments such as laser, intense pulse light, chemical peeling and fillers in the treatment area within one year; 2. Smokers; 3. People with scar or skin diseases (such as vitiligo, lichen planus, etc.) that can easily induce Koebner phenomenon; 4. Without control of other facial skin diseases, or a history of facial herpes simplex, varicella zoster virus infection, or a history of skin tumors, discoid lupus erythematosus and other serious skin diseases; 5. Those who have been treated with systemic retinoic acid in the past three months, minocycline, quinolone and other photosensitive drugs in the past one month, or those who have photosensitive history; 6. Darkening of facial skin due to recent exposure; 7. Pregnant women, lactation, or have serious diseases such as cardiac and cerebrovascular, liver and kidney dysfunction; or the person that installs pacemaker, defibrillator; 8. Patients with mental illness or other potential reasons who cannot complete treatment and follow-up plans; 9. Participated in other clinical trials in recent 1 month; 10. Other conditions that may result in adverse outcomes for patients; 11. Pigmented diseases, acne or other skin diseases in the treatment area that may interfere the evaluation.

Design outcomes

Primary

MeasureTime frame
Number of pores;

Secondary

MeasureTime frame
Sebum;TEWL;

Countries

China

Contacts

Public ContactShuxian Yan

Huashan Hospital affiliated to Fudan University

shuxianyan0225@126.com+86 13817200326

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026